PolyPeptide

Polypeptide 1H26 results

13/08/26 -"PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus was on the CHF1.5bn offer from Samsung Biologics ..."

PDF page sample
Pages
51
Language
English
Published on
13/08/26
Download
You may also be interested by these reports :
13/08/26
PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus ...
13/08/26
The Q2 results surpassed expectations, backed by the unrelenting growth of Dupixent and the impressive uptake of some newly launched medicines. ...
12/08/26
With the Astra-BMS merger idea likely being shelved after apprehensions raised by various analysts/investors, we re-float the idea of an Astra-GSK ...
04/08/26
Imagine a restaurant having to serve its customers by ordering outside food. We cannot resist drawing parallels between this hypothetical scenario ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO